Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Eur J Pharm Biopharm ; 171: 11-18, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34990784

ABSTRACT

In this study, the use of a microwave reactor, which allowed high input of energy into a pressurised system in a short period of time, was investigated for preparation of lipid nanoparticles (LNPs). The aim was to optimise the formulation process by reducing manufacturing time. Two types of LNPs were prepared; non-ionic surfactant vesicles (NISV) and bilosomes (modified NISV incorporating bile salts), with a model antigen (tetanus toxoid, TT) and the immune response induced after mucosal (nasal and oral, respectively) administration was assessed. The TT loaded LNPs were characterised in terms of particle size, size distribution, morphology, and entrapment efficiency. Immunisation was evaluated by lethal challenge with tetanus toxin in an animal model. The efficiency of vaccination was evaluated by measuring the anti-TT IgG antibody levels in the vaccinated animals. Bilosomes formed by this method showed an immunogen entrapment efficiency of ∼30% which was significantly (p < 0.05) higher than entrapment efficiency in the NISV. The percentage of animals that survived when challenged with tetanus toxin correlated with the level of IgG determined in the serum of mice immunised with LNPs by the mucosal route. Moreover, there were significant (p < 0.05) differences between orally and nasally immunised groups. Animal groups immunised bilosomes via the oral route showed the highest level of IgG (1.2 ± 0.13) compared to the positive control, LN + Xn, and no immunised group. Similarly, groups immunised via the nasal route showed significantly (p < 0.0001) higher titres compared with the control group. Mucosal TT was capable of inducing systemic specific IgG anti-TT responses that were higher than the parenteral vaccine.


Subject(s)
Drug Carriers , Liposomes , Mucous Membrane/metabolism , Nanoparticles , Tetanus Toxoid/pharmacokinetics , Administration, Intranasal , Administration, Oral , Animals , Immunization , Immunoglobulin G/immunology , Mice , Microwaves , Models, Animal , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/chemistry , Tetanus Toxoid/immunology
2.
Int J Biol Macromol ; 91: 381-93, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27246374

ABSTRACT

In drug delivery research, several toxic chemical crosslinkers and non-toxic ionic crosslinkers have been exploited for the synthesis of microparticles from acetic acid soluble chitosan. This paper hypothesized the implementation of sodium potassium tartrate (SPT) as an alternative crosslinker for sodium tripolyphosphate (TPP) and SPT/TPP co-crosslinkers for synthesis of the microparticles using water soluble chitosan (WSC) for encapsulation of Bovine serum albumin (BSA) as a model protein, and Tetanus toxoid (TT) as a model vaccine. The crosslinking was confirmed by FT-IR, SEM with EDS. The XRD entailed molecular dispersion of proteins and thermal analysis confirmed the higher stability of STP/TPP co-crosslinked formulations. The resultant microparticles were exhibiting crosslinking degree (52-67%), entrapment efficiency (72-80%), particle size (0.3-1.7µm), zeta potential (+24 to 46mV) and mucoadhesion (41-68%). The superiority of SPT over TPP was confirmed by higher crosslinking degree and entrapment efficiency. However, co-crosslinking were advantageous in higher regression values for Langmuir adsorption isotherm, slower swelling tendency and extended 30days controlled in-vitro release study. TT release obeyed the Quasi-Fickian diffusion mechanism for single and cocrosslinked formulations. Overall, in crosslinking of chitosan as biological macromolecules, STP/TPP may be alternative for single ionic crosslinked formulations for protein antigen delivery.


Subject(s)
Antigens, Bacterial/chemistry , Chitosan/chemistry , Cross-Linking Reagents/chemistry , Polyphosphates/chemistry , Serum Albumin, Bovine/chemistry , Tartrates/chemistry , Tetanus Toxoid/chemistry , Animals , Cattle , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Serum Albumin, Bovine/pharmacokinetics , Tetanus Toxoid/pharmacokinetics
3.
Nanomedicine (Lond) ; 10(7): 1077-91, 2015.
Article in English | MEDLINE | ID: mdl-25929566

ABSTRACT

AIM: Present study reports the development of divalent vaccine with enhanced protection, permeation and presentation following peroral immunization. MATERIALS & METHODS: Layersomes were prepared by layer-by-layer tuning of polyelectrolytes on liposomes template. The developed system was evaluated for in vitro stability of antigen and layersomes, cell-based assays and immunization experiments in mice. RESULTS: Layersomes exhibited enhanced stability in simulated biological fluids, still preserving the integrity, biological activity and conformational stability of toxoids. Layersomes also exhibited complete and protective (>0.1 IU/ml) immunostimulatory response include serum IgG titer, mucosal sIgA titer and cytokines (IL-2 and IFN-γ) levels following peroral administration. CONCLUSION: The positive findings of proposed strategy are expected to contribute significantly in the field of stable liposomes technology and peroral immunization.


Subject(s)
Diphtheria Toxoid/administration & dosage , Liposomes/chemistry , Tetanus Toxoid/administration & dosage , Administration, Oral , Animals , Caco-2 Cells , Cell Line , Diphtheria/immunology , Diphtheria/prevention & control , Diphtheria Toxoid/immunology , Diphtheria Toxoid/pharmacokinetics , Female , Humans , Immunization , Immunoglobulin A/analysis , Immunoglobulin A/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Interferon-gamma/blood , Interferon-gamma/immunology , Interleukin-2/blood , Interleukin-2/immunology , Mice , Mice, Inbred BALB C , Tetanus/immunology , Tetanus/prevention & control , Tetanus Toxoid/immunology , Tetanus Toxoid/pharmacokinetics
4.
J Control Release ; 183: 43-50, 2014 Jun 10.
Article in English | MEDLINE | ID: mdl-24657807

ABSTRACT

Protective mucosal immune responses are thought best induced by trans-mucosal vaccination, providing greater potential to generate potent local immune responses than conventional parenteral vaccination. However, poor trans-mucosal permeability of large macromolecular antigens limits bioavailability to local inductive immune cells. This study explores the utility of polymeric penetration enhancers to promote trans-mucosal bioavailability of insulin, as a biomarker of mucosal absorption, and two vaccine candidates: recombinant HIV-1 envelope glycoprotein (CN54gp140) and tetanus toxoid (TT). Responses to vaccinating antigens were assessed by measurement of serum and the vaginal humoral responses. Polyethyleneimine (PEI), Dimethyl-ß-cyclodextrin (DM-ß-CD) and Chitosan enhanced the bioavailability of insulin following intranasal (IN), sublingual (SL), intravaginal (I.Vag) and intrarectal (IR) administration. The same penetration enhancers also increased antigen-specific IgG and IgA antibody responses to the model vaccine antigens in serum and vaginal secretions following IN and SL application. Co-delivery of both antigens with PEI or Chitosan showed the highest increase in systemic IgG and IgA responses following IN or SL administration. However the highest IgA titres in vaginal secretions were achieved after IN immunisations with PEI and Chitosan. None of the penetration enhancers were able to increase antibody responses to gp140 after I.Vag immunisations, while in contrast PEI and Chitosan were able to induce TT-specific systemic IgG levels following I.Vag administration. In summary, we present supporting data that suggest appropriate co-formulation of vaccine antigens with excipients known to influence mucosal barrier functions can increase the bioavailability of mucosally applied antigens promoting the induction of mucosal and systemic antibody responses.


Subject(s)
Drug Carriers/chemistry , Polymers/chemistry , Tetanus Toxoid/immunology , env Gene Products, Human Immunodeficiency Virus/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/immunology , Administration, Mucosal , Animals , Chitosan/chemistry , Female , Immunity, Humoral , Immunity, Mucosal , Immunoglobulin A/blood , Immunoglobulin A/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Mice, Inbred BALB C , Polyethyleneimine/chemistry , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/pharmacokinetics , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , beta-Cyclodextrins/chemistry , env Gene Products, Human Immunodeficiency Virus/administration & dosage , env Gene Products, Human Immunodeficiency Virus/pharmacokinetics
5.
Int J Nanomedicine ; 9: 937-50, 2014.
Article in English | MEDLINE | ID: mdl-24611010

ABSTRACT

PURPOSE: The aim of the study was to load a model antigen, tetanus toxoid (TT), in poly-ε-caprolactone nanoparticles (PCL NPs) of two size ranges, ie, mean 61.2 nm (small) and 467.6 nm (large), and study its effect on macrophage polarization as well as antigen presentation in human monocyte-derived macrophages in vitro, along with humoral and cell-mediated immune (CMI) response generated in Swiss albino mice following immunization with the TT-loaded NPs. MATERIALS AND METHODS: PCL NPs were synthesized by solvent evaporation. The antigen-loaded PCL NPs were characterized for size, zeta potential, and protein-release kinetics. Swiss albino mice were immunized with the antigen-loaded PCL NPs. Flow cytometry was used to quantify interferon-γ- and interleukin-4-secreting cluster of differentiation (CD)4(+) and CD8(+) T cells in the spleen, and enzyme-linked immunosorbent assay was used to quantify anti-TT antibody levels in the serum of immunized mice. RESULTS: Small PCL NPs generated an M1/M2 type polarization of human blood monocyte-derived macrophages and T helper (Th)1/Th2 polarization of autologous CD4(+) T cells. Efficient CD8(+) T-cell responses were also elicited. Large PCL NPs failed to cause any type of macrophage polarization. They did not elicit efficient CD8(+) T-cell responses. CONCLUSION: TT-loaded small PCL NPs were able to generate persistent and strong CMI and humoral responses against TT 2 months after single injection in mice without booster dose. This biodegradable nanoadjuvant system may help to develop single-shot immunization for prolonged immunity without booster doses. The capability of enhanced CMI response may have high translational potential for immunization against intracellular infection.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/chemistry , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Vaccines/administration & dosage , Animals , Antigen Presentation , Caproates/chemistry , Cell Line , Female , Humans , Lactones/chemistry , Macrophages/immunology , Mice , Nanomedicine , Nanoparticles/ultrastructure , Nanotechnology , Particle Size , T-Lymphocyte Subsets/immunology , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/pharmacokinetics , Vaccines/pharmacokinetics
6.
Biologicals ; 39(6): 404-16, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21985899

ABSTRACT

We present the results of a collaborative study for the establishment of a replacement International Standard (IS) for Tetanus Toxoid Adsorbed. Two candidate preparations were included in the study, one of which was established as the 4th IS for Tetanus Toxoid Adsorbed at the WHO Expert Committee on Biological Standardization meeting in October 2010. This preparation was found to have a unitage of 490 IU/ampoule, based on calibration in guinea pig challenge assays. Results from mouse challenge assays suggest that the relative performance of two candidate preparations may differ significantly between guinea pigs and mice. The authors note that the number of laboratories that performed guinea pig challenge assays, which are used to calibrate and assign IU, is much lower than in previous collaborative studies and this may have implications for calibration of replacement standards in the future. The issue of assigning separate units to the IS for guinea pig and mouse assays is discussed. The study also assessed performance of the replacement standard in serological assays which are used as alternative procedures to challenge assays for tetanus potency testing. Results suggest that the replacement standard is suitable for use as the reference vaccine in serological assays.


Subject(s)
Biological Assay/standards , Laboratories/standards , Tetanus Toxoid/standards , Adsorption , Animals , Biological Assay/methods , Calibration , Guinea Pigs , International Cooperation , Mice , Reference Standards , Reproducibility of Results , Species Specificity , Tetanus Toxoid/immunology , Tetanus Toxoid/pharmacokinetics
8.
Curr Drug Deliv ; 6(3): 297-04, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19604144

ABSTRACT

Polymeric microspheres containing diphtheria and tetanus toxoids were prepared without protein stabilizers. A vaccine containing 2 Lf(tetanus) and 0.4 Lf(diphtheria) was injected either in BALB/c mice or in guinea-pigs. As control, a group received the alum-adsorbed unencapsulated toxoids. In mice, on day 44 one group and control received a booster and at day 111 the other group received the same booster dose. Before de booster, all groups had very low neutralizing antibodies, as determined by Toxin binding inhibition assay. One week after booster all groups had high antibody titers, especially those immunized with microencapsulated vaccine, which were at least 5 times higher than those immunized with alum vaccine for both antigens. Besides, guinea pigs receiving lower dose had antibodies titers as high as 60 UI/mL, and 30 times higher than those immunized with alum vaccine. Therefore by using an encapsulated vaccine without any kind of protein stabilizer we were able to induce in vivo protective responses irrespective of observed in vitro protein degradation by HPLC. Manipulating the vaccination schedule at the same time to the toxoids encapsulation does not only increase the antibody titers but also their specificity.


Subject(s)
Diphtheria-Tetanus Vaccine/administration & dosage , Diphtheria-Tetanus Vaccine/immunology , Lactic Acid/chemistry , Microspheres , Polyglycolic Acid/chemistry , Adjuvants, Immunologic , Animals , Antibodies/blood , Antibodies/immunology , Biological Availability , Diphtheria Toxoid/administration & dosage , Diphtheria Toxoid/immunology , Diphtheria Toxoid/pharmacokinetics , Diphtheria-Tetanus Vaccine/chemistry , Drug Compounding , Female , Guinea Pigs , Immunoglobulin G/blood , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Particle Size , Polylactic Acid-Polyglycolic Acid Copolymer , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/immunology , Tetanus Toxoid/pharmacokinetics , Vaccination/methods
9.
Eur J Pharm Sci ; 38(1): 18-28, 2009 Aug 12.
Article in English | MEDLINE | ID: mdl-19467323

ABSTRACT

This study was aimed at understanding the role of alum in improving the immunogenicity of biodegradable polymer particle entrapped antigens. Presence of alum formed a fine network around PLA particles holding them together and promoted attachment of higher number of particles on macrophage surface for a considerable period of time. Use of alum lowered the burst release of the entrapped antigen from particles and thereafter also reduced the cumulative release of antigen from particles. Apart from this, PLA microparticles alone induced macrophages to release TNF-alpha similar to that induced by alum. However admixture of PLA particles and alum enhanced the secretion of TNF-alpha from 876pg/ml at 6h to 3500pg/ml at 24h which was higher than that induced by alum adsorbed TT. Immunization with admixture of antigen loaded polylactide (PLA) microparticles (2-8microm) and alum improved the antibody titers almost twice than that achieved from particle alone in experimental animals. Single point immunization with particle entrapped antigens and alum also elicited antibody titers comparable to two doses of alum adsorbed tetanus toxoid (TT) or diphtheria toxoid (DT). Our results suggest that presence of alum acts in multiple ways to improve the antibody titers of polymer particles entrapped antigens. Such co-operative adjuvant action of alum and polymer particles can be exploited to improve the immunogenicity of other antigens.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Aluminum Hydroxide/immunology , Antigens/administration & dosage , Antigens/immunology , Drug Carriers/metabolism , Polyesters/chemistry , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/pharmacology , Aluminum Hydroxide/chemistry , Aluminum Hydroxide/pharmacology , Animals , Antibody Formation/immunology , Biological Availability , Cell Line , Cell Survival/drug effects , Cytokines/metabolism , Drug Carriers/chemistry , Drug Carriers/pharmacology , Female , Immunoglobulin G/blood , Immunoglobulin G/immunology , Macrophages/drug effects , Macrophages/immunology , Macrophages/metabolism , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/metabolism , Mice , Mice, Inbred BALB C , Microscopy, Electron, Scanning , Particle Size , Rats , Rats, Wistar , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/immunology , Tetanus Toxoid/pharmacokinetics , Vaccination/methods , Vaccines/administration & dosage , Vaccines/chemistry , Vaccines/immunology
10.
Int J Pharm ; 368(1-2): 123-8, 2009 Feb 23.
Article in English | MEDLINE | ID: mdl-19013510

ABSTRACT

Low-frequency ultrasound application is known to increase the skin's permeability to large molecules such as vaccines, and to enable transcutaneous immunisation. Sodium dodecyl sulphate (SDS) - a skin irritant - is often included in the coupling medium at 1% (w/v), as this has been found to enhance skin permeability. In this paper we show, for the first time, the feasibility of low-frequency ultrasound-assisted transcutaneous immunisation in the absence of SDS. Antibody titres were strongly influenced by experimental conditions. SDS presence in the coupling medium increased antibody titres, though a lower concentration of 0.5% (w/v) generated much higher titres than the commonly used 1% (w/v), despite causing less skin damage. A lower ultrasound duty cycle of 10% generated higher antibody titres than a duty cycle of 20%, also despite causing lower skin damage. Such lack of correlation between skin damage and immune responses indicates that enhancement of skin permeability to topically applied antigen (as indicated by changes in skin integrity) was not the main mechanism of low-frequency ultrasound-assisted skin immunisation.


Subject(s)
Administration, Cutaneous , Drug Delivery Systems , Immunization , Phonophoresis , Skin/diagnostic imaging , Tetanus Toxoid/administration & dosage , Animals , Female , Mice , Mice, Inbred BALB C , Skin/metabolism , Skin Absorption/drug effects , Sodium Dodecyl Sulfate/administration & dosage , Sodium Dodecyl Sulfate/metabolism , Surface-Active Agents/administration & dosage , Surface-Active Agents/metabolism , Tetanus Toxoid/pharmacokinetics , Ultrasonography
11.
J Control Release ; 131(2): 113-20, 2008 Oct 21.
Article in English | MEDLINE | ID: mdl-18700159

ABSTRACT

One of the most important anthropic missions is preventing the global spread of infectious diseases. Vaccination is the only available preventive treatment for infectious diseases, but the availability of vaccines in developing countries is not adequate. We report a simple, easy-to-use, noninvasive hydrogel patch transcutaneous vaccination system. Antigen (Ag)-specific IgG production was induced by applying an Ag-immersed patch to non-pretreated mouse auricle or hairless rat back skin. Immunofluorescence histochemical analysis revealed that Langerhans cells resident in the epidermal layer captured the antigenic proteins delivered by the hydrogel patch, which promoted the penetration of antigenic proteins through the stratum corneum, and that Ag-capturing Langerhans cells migrated into draining lymph nodes. Humoral immunity elicited by our transcutaneous vaccination system demonstrated neutralizing activity in both adenoviral infection and passive-challenge tetanus toxin experiments. The use of this hydrogel patch transcutaneous vaccination system will facilitate the global distribution of effective and convenient vaccines.


Subject(s)
Bacterial Infections/prevention & control , Drug Carriers/administration & dosage , Hydrogel, Polyethylene Glycol Dimethacrylate/administration & dosage , Vaccination/methods , Vaccines/administration & dosage , Virus Diseases/prevention & control , Administration, Cutaneous , Animals , Antibody Formation/immunology , Antigens, Viral/administration & dosage , Bacterial Infections/immunology , Capsid Proteins/administration & dosage , Capsid Proteins/pharmacokinetics , Cell Line , Drug Delivery Systems , Female , Humans , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred ICR , Rats , Rats, Hairless , Skin Absorption , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/pharmacokinetics , Vaccines/pharmacokinetics , Virus Diseases/immunology
12.
Pediátrika (Madr.) ; 27(2): 58-71, feb. 2007. ilus, tab
Article in Es | IBECS | ID: ibc-64702

ABSTRACT

La vacuna que contiene polisacárido de meningococodel grupo C de-O-acetilado, conjugada con toxoidetetánico (GCMP-TT), se ha autorizado en 32países y se ha incorporado en un programa de vacunaciónrutinaria en el Reino Unido. Rápidamentese ha acumulado una gran experiencia, que es elobjeto de este meta-análisis, sobre la inmunogenicidad,seguridad y posología de GCMP-TT, así comosobre su impacto epidemiológico. GCMP-TT ha demostradoser efectiva tras una dosis única en individuosmayores de 12 meses de edad y su posologíainicial especificaba tres dosis en lactantes. Sin embargo,según un ensayo clínico reciente, la posologíase redujo a dos dosis en lactantes. La tasa deprotección recogida, definida como la proporción deindividuos con títulos de anticuerpos bactericidas ensuero (SBA) ≥1:8, fue del 99,4% (CI, 98.2-99.9%) ensiete estudios clínicos que abarcan todos los gruposde edad. Se han demostrado respuestas fuertes aGCMP-TT con respecto a SBA, niveles de IgG y deavidez a los anticuerpos. En la farmacovigilanciadespués de la comercialización, que abarca >12 x106 GCMP-TT dosis distribuidas por todo el mundo,la vacuna ha sido bien tolerada con una tasa de incidenciade 0,01% para todos los tipos de efectos adversosmás comúnmente encontrados. Después deuna campaña de vacunación general en el ReinoUnido, en la que a los niños de 5-8 años se les dioprimeramente GCMP-TT, se observó una disminucióndel 93% en la incidencia de enfermedad meningocócica.A la vista de esta inmunogenicidad, seguridady adaptación potencial al uso en lactantes enprogramas de posología reducida, la vacuna GCMPTTmarca un mayor avance sobre las vacunas depolisacárido predecesoras en la prevención de enfermedadmeningocócica C


A conjugate vaccine comprised of de-O-acetylatedgroup C meningococcal polysaccharide coupledto tetanus toxoid (GCMP-TT) has been licensed in32 countries and incorporated in a comprehensiveUK vaccination program. Extensive evidence, formingthe subject of this meta-analysis, has rapidlyaccumulated on the immunogenicity, safety and posologyof GCMP-TT as well as its epidemiologicalimpact. GCMP-TT has been shown effective after asingle dose in individuals > 12 months of age, andinitial posology specified three doses in infants. However,based on a recent clinical trial, posology wasreduced to two doses in infants. Pooled protectionrate, defined as proportion of subjects with serumbactericidal antibody (SBA) levels 1:8, was 99.4%(CI, 98.2-99.9%) in 7 clinical trials covering all agegroups. Robust responses to GCMP-TT have been demonstrated with respect to SBA, IgG levels andantibody avidity. In post-marketing pharmacosurveillanceencompassing > 12*106 GCMP-TT doses distributedworldwide, the vaccine has been well toleratedwith an incidence rate of 0.01% for all the mostcommonly encountered types of adverse events. Aftera catch-up UK vaccination campaign where 5-8year old children were primarily given GCMP-TT, a93% decline in meningococcal disease incidencewas observed. In view of its immunogenicity, safetyand potential suitability for use among infants in reduceddose schedules, GCMP-TT appears to marka major advance over predecessor polysaccharidevaccines for the prevention of meningococcal C disease


Subject(s)
Humans , Pneumococcal Vaccines/pharmacokinetics , Meningococcal Infections/prevention & control , Streptococcus pneumoniae/pathogenicity , Tetanus Toxoid/pharmacokinetics , Vaccines, Conjugate/analysis , Dose-Response Relationship, Immunologic , Immunization Schedule
13.
Int J Pharm ; 292(1-2): 43-52, 2005 Mar 23.
Article in English | MEDLINE | ID: mdl-15725552

ABSTRACT

Previous studies have shown that PLA-PEG nanoparticles (NP) are able to enhance the transport of the encapsulated model protein, tetanus toxoid (TT), across the rat nasal mucosa. The aim of this work was to study if the size of PLA-PEG particles affects the nasal transport of the encapsulated protein and, also, the potential contribution of blank nanoparticles to the transport of the free protein. To achieve this purpose, 125I-TT was encapsulated into PLA-PEG particles of different sizes (200 nm, 1.5, 5 and 10 microm) prepared by the water-in-oil-in-water solvent evaporation technique. Firstly, in order to investigate the carrier role of the particles, two series of either conscious or anaesthetized rats were nasally treated with 125I-TT-loaded NP, free 125I-TT, and a physical mixture of blank NP and free 125I-TT. Secondly, the influence of the particle size on the nasal transport of TT encapsulated into PLA-PEG particles was evaluated in conscious rats. The amount of radioactivity recovered in the blood compartment, lymph nodes and other relevant tissues was monitored for up to 24h. Finally, the nasal bioavailability of 125I-TT-loaded PLA-PEG NP was calculated. The results indicated that the use of anaesthesia enhances the transport of 125I-TT and that the physical presence of PLA-PEG NP does not affect the transport of the toxoid. In contrast, when TT was encapsulated into the particles its transport across the nasal mucosa of conscious rats was significantly enhanced. Furthermore, the efficacy of this transport was related to the particle size, reaching the most important transport for the smallest particle size. The intensity of this transport was also illustrated by the high nasal bioavailability of TT encapsulated into nanoparticles (200 nm) (F = 70-80%). These results led us to conclude that PLA-PEG NP can be accepted as nasal protein carriers for nasal administration.


Subject(s)
Carrier Proteins/pharmacokinetics , Olfactory Mucosa/metabolism , Particle Size , Polyesters/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , Administration, Intranasal , Animals , Biological Availability , Carrier Proteins/chemistry , Drug Evaluation, Preclinical/methods , Iodine Radioisotopes , Male , Nanostructures , Olfactory Mucosa/drug effects , Polyesters/chemistry , Polyethylene Glycols/chemistry , Rats , Rats, Sprague-Dawley , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/metabolism , Tetanus Toxoid/pharmacokinetics
14.
J Aerosol Med ; 17(2): 174-85, 2004.
Article in English | MEDLINE | ID: mdl-15294069

ABSTRACT

This report presents an overview of the potential of nanoparticles as nasal carriers for drug/vaccine administration. In addition, this report shows, for the first time, the efficacy of polylactic acid nanoparticles coated with a hydrophilic polyethyleneglycol coating (PEG-PLA nanoparticles) as carriers for the nasal transport of bioactive compounds. For this purpose, tetanus toxoid (TT), a high molecular weight protein (Mw 150,000 Da), was chosen as a model antigen and encapsulated in the PEG-PLA nano- and microparticles (200 nm and 1.5 microm respectively). These nanosystems were first characterized for their stability in the presence of lysozyme and also for their size, electrical charge, loading efficiency, in vitro release of antigenically active toxoid and afterwards, these formulations were administered intranasally to mice and the systemic and mucosal anti-tetanus responses were evaluated for up to 24 weeks. Additionally, PEG-PLA particles labeled with rhodamine 6G were administered intranasally to rats in order to visualize their interaction with the nasal mucosae by fluorescence microscopy. Their behavior was compared with that of the well known PLA nanoparticles (200 nm). The results showed that PLA nanoparticles suffered an immediate aggregation upon incubation with lysozyme, whereas the PEG-coated nanoparticles remained totally stable. The antibody levels elicited following i.n. administration of PEG-coated nanoparticles were significantly higher than those corresponding to PLA nanoparticles. Furthermore, PEG-PLA nanoparticles generated an increasing and a long lasting response. The qualitative fluorescence microscopy studies revealed that PEG-PLA particles are able to cross the rat nasal epithelium. These studies indicate that the PEG coating around the particles has a role in stabilizing PLA particles in mucosal fluids and that it facilitates the transport of the nanoencapsulated antigen, hence eliciting a high and long lasting immune response.


Subject(s)
Drug Carriers , Polyethylene Glycols/pharmacology , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/pharmacokinetics , Administration, Intranasal , Animals , Biological Availability , Bronchoalveolar Lavage Fluid/chemistry , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Immunization/methods , Mice , Microscopy, Fluorescence , Models, Animal , Particle Size , Peritoneal Lavage , Rats , Saliva/chemistry , Sensitivity and Specificity , Tissue Distribution , Vaccines/administration & dosage
15.
Pharm Res ; 19(8): 1105-13, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12240935

ABSTRACT

PURPOSE: Mucosal delivery of vaccine-loaded nanoparticles (NP) is an attractive proposition from an immunologic perspective. Although numerous NP preparation methods are known, sufficient antigen loading of NP remains a challenge. The aim of this study was to evaluate adsorptive loading of NP with a negatively charged surface structure using tetanus toxoid (TT) as a model vaccine. METHODS: Blank NP, consisting of poly(sulfobutyl-polyvinyl alcohol)-g-(lactide-co-glycolide), as well as poly(lactide-co-glycolide) NP were prepared by a solvent displacement technique. The use of polymers with different degrees of substitution resulted in NP with different negative surfaces charges. Adsorption of TT to NP was performed varying to NP surface properties, protein equilibrium concentration, and loading conditions. RESULTS: The protein adsorption was controlled by NP surface properties, and maximum TT adsorption occurred at highly negatively charged NP surfaces. Results from isothermal titration calorimetry and zeta-potential measurement suggest an adsorption process governed by electrostatic interactions. The adsorption followed the Langmuir isotherm in the concentration ranges studied. TT withstood this gentle loading procedure in a nonaggregated, enzyme-linked immunoabsorbant assay-active form. CONCLUSION: The results demonstrate that negatively charged NP consisting of poly(sulfobutyl-polyvinyl alcohol)-g-(lactide-co-glycolide) are suitable for adsorptive loading with TT and may have potential for mucosal vaccination.


Subject(s)
Nanotechnology/methods , Polyglactin 910/analogs & derivatives , Polyglactin 910/pharmacokinetics , Polyvinyl Alcohol/analogs & derivatives , Polyvinyl Alcohol/pharmacokinetics , Proteins/pharmacokinetics , Tetanus Toxoid/pharmacokinetics , Adsorption/drug effects , Polyglactin 910/administration & dosage , Polyvinyl Alcohol/administration & dosage , Proteins/administration & dosage , Tetanus Toxoid/administration & dosage
16.
Int J Pharm ; 189(1): 75-9, 1999 Oct 28.
Article in English | MEDLINE | ID: mdl-10518687

ABSTRACT

In light of growing interest in the intranasal route as a non-invasive mode of immunisation, we have investigated the relationship between the volume of liquid instilled into the nasal passages and the development of subsequent immunological responses. Groups of six mice were intranasally immunised with soluble or microsphere encapsulated tetanus toxoid on days 1, 14 and 28 of the experiment. Microsphere suspensions and tetanus toxoid solutions were nasally instilled in two different volumes of buffer (10 or 50 microl). Nasal instillation of microspheres in 10 microl of buffer generated statistically depressed (P<0.001) tertiary serum anti-toxoid IgG responses in comparison to animals immunised with 10 or 50 microl of soluble vaccine, or 50 microl of microsphere suspension. Relative to other treatments, nasal inoculation of encapsulated toxoid suspended in 50 microl generated statistically (P<0.05) superior levels of specific IgG and IgA antibodies in day 49 lung wash samples. When radiolabelled microspheres were nasally instilled into mouse nares in 50-microl volumes of buffer, a significant portion of the dose (48%) entered the lungs (P<0.001), whereas more particles remained in the nasal passages when a smaller (10 microl) volume of suspension was given (P<0.001). These biodistribution and immunological data indicate that to generate optimal bronchopulmonary and systemic responses in concert following nasal administration, microparticulated vaccines should be administered with a delivery device that targets the formulation to distal regions of the nasal passages and the lower respiratory tract.


Subject(s)
Drug Compounding , Drug Delivery Systems , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/immunology , Administration, Intranasal , Animals , Female , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Microspheres , Solutions , Tetanus Toxoid/pharmacokinetics , Tissue Distribution
17.
Pharm Res ; 16(5): 682-8, 1999 May.
Article in English | MEDLINE | ID: mdl-10350011

ABSTRACT

PURPOSE: Previous work on the encapsulation of proteins and antigens in poly(lactic-co-glycolic acid) (PLGA) microspheres has led to the conclusion that microencapsulated antigens are frequently inactivated due to their interaction with the polymer. To improve the compatibility of the antigen with the polymer, we have devised a novel microencapsulated system consisting of a blend of PLGA 50:50 and poloxamer 188 (Pluronic F68) and applied it to the delivery of tetanus antigen. METHODS: Tetanus toxoid was encapsulated in microspheres containing different amounts of poloxamer using an anhydrous procedure based on an oil-in-oil solvent extraction process. The compatibility of the polymers was studied by Fourier transform infrared (FT-IR) spectroscopy. Microspheres were assayed in vitro and in vivo for their ability to deliver active antigen for extended periods of time. RESULTS: Analysis by FT-IR spectroscopy evidenced the miscibility of both polymers by a hydrogen bonding mechanism. In vitro release studies revealed that microspheres containing poloxamer released antigenically active TT, in a pulsatile manner, for up to 50 days. In addition, it was observed that the intensity and duration of the pulses were dependent on both poloxamer content and TT loading in the microspheres. The in vivo evaluation of this new system showed that the neutralizing antibodies elicited by the TT encapsulated in poloxamer-PLGA microspheres were considerably higher and more prolonged than those obtained after administration of the aluminum phosphate-adsorbed toxoid. CONCLUSIONS: These results indicate the importance of devising new microencapsulation approaches specially adapted for preserving the activity of protein antigens incorporated within PLGA microspheres.


Subject(s)
Biocompatible Materials/pharmacokinetics , Drug Delivery Systems/methods , Excipients/pharmacokinetics , Lactic Acid/pharmacokinetics , Poloxamer/pharmacokinetics , Polyglycolic Acid/pharmacokinetics , Polymers/pharmacokinetics , Tetanus Toxoid/pharmacokinetics , Animals , Antigens/drug effects , Antigens/immunology , Biocompatible Materials/analysis , Drug Compounding , Excipients/analysis , Hydrogen Bonding , Immunization/methods , Immunoglobulin G/immunology , Immunoglobulin G/pharmacology , Lactic Acid/analysis , Mice , Microscopy, Electron, Scanning , Neutralization Tests , Oils , Particle Size , Poloxamer/analysis , Polyglycolic Acid/analysis , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers/analysis , Solvents , Spectroscopy, Fourier Transform Infrared , Tetanus Toxoid/immunology
18.
Am J Reprod Immunol ; 40(5): 347-51, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9870078

ABSTRACT

PROBLEM: The transport of various proteins across the human placenta was investigated by comparing maternal and fetal concentrations of tetanus antigen (TT-AG), anti-tetanus (TT)-immunoglobulin G (IgG) (following maternal vaccination), IgA, human chorionic gonadotropin (hCG), human placental lactogen (hPL), and alpha-fetoprotein (AFP) at term. METHOD OF STUDY: The concentrations of the six proteins were determined using enzyme-linked immunosorbent assay in serum of maternal venous and umbilical (fetal) vein samples obtained at delivery from uncomplicated term pregnancies (n = 16). RESULTS: The ratios (mean +/- standard deviation) of fetal (umbilical) to maternal level were 1.41 +/- 0.33 (anti-TT-IgG), 0.91 +/- 0.37 (TT-AG), 0.002 +/- 0.001 (IgA), 0.003 +/- 0.001 (hCG), and 0.008 +/- 0.004 (hPL), while the maternal:fetal concentration ratio of AFP was 0.002 +/- 0.002. IgA, hCG, hPL, and AFP showed a close correlation between maternal and fetal levels varying between r2 = 0.47 to 0.73 (P < 0.004-0.0001). Because AFP is produced by the fetus while IgA originates in the mother, the appearance of small amounts of these two proteins in the maternal or fetal compartment, respectively, suggests a slow rate of diffusion following a high concentration gradient. The detection of hCG and hPL in fetal serum is also interpreted as diffusion from the maternal into the fetal blood. Anti-TT-IgG has a significantly higher concentration in the fetal as compared with the maternal serum, which is in line with the well-documented active transfer of IgG. Fetal TT-antigen levels were similar to maternal concentrations, showing a close correlation (r2 = 0.74, P < 0.0001) between the two proteins. CONCLUSIONS: The correlation between maternal and fetal concentrations of various proteins like IgA (150,000 Da), hCG (42,000 Da), and hPL (21,000 Da) suggests passive diffusion of these macromolecules across the placenta from the maternal to the fetal side, albeit at a slow rate. A similar process is postulated for AFP (70,000 Da) diffusing in the opposite direction from the fetus to the mother. There was no significant difference between the transplacental fetomaternal gradient of IgA and hCG and the maternal-fetal gradient of AFP. In view of the substantially larger volume of circulating maternal as compared with fetal blood, a significantly higher rate of crossing of AFP as compared with the other proteins must be assumed. It is uncertain whether a difference in the rate of transplacental transfer in the two directions or an additional source of AFP production in the maternal compartment explains the high maternal level. Anti-TT-IgG concentration is significantly higher in fetal than in maternal serum suggesting active transfer from the mother to the fetus. Furthermore, there is considerable transfer of TT-AG and a close correlation of fetal:maternal ratios of anti-TT-IgG (150,000 Da) and TT-AG (150,000 Da) could be an indication for a specific transfer of the antigen antibody complex.


Subject(s)
Placenta/metabolism , Proteins/metabolism , Biological Transport , Chorionic Gonadotropin/blood , Female , Humans , Immunoglobulin A/blood , Immunoglobulin A/metabolism , Immunoglobulin G/blood , Immunoglobulin G/metabolism , Maternal-Fetal Exchange , Placental Lactogen/metabolism , Pregnancy , Proteins/pharmacokinetics , Tetanus Toxoid/blood , Tetanus Toxoid/immunology , Tetanus Toxoid/pharmacokinetics , alpha-Fetoproteins/metabolism
19.
J Invest Dermatol ; 110(5): 762-6, 1998 May.
Article in English | MEDLINE | ID: mdl-9579542

ABSTRACT

Recently, a novel type of dendritic antigen-presenting cell has been identified in the dermis of normal human and mouse skin. These dermal dendritic cells (DDC) occur in higher numbers than epidermal Langerhans cells, represent a distinct differentiation pathway of dendritic cells, and are as potent as Langerhans cells in the activation of superantigen specific T cells. As yet, nothing is known about their capacity to take up, process, and present soluble protein antigens. We used the model of tetanus toxoid (TT) driven T cell proliferation to address these questions. To test for active internalization of TT protein, gold labeled TT was incubated with Langerhans cells and DDC and could be traced to multivesicular endo-lysosomal compartments. DDC internalize TT through a receptor-mediated, clathrin-independent pathway, whereas Langerhans cells predominantly use macropinocytosis. To verify that DDC process TT by the exogenous pathway of antigen presentation, we pulsed DDC with TT protein or TT peptide after preincubation with chloroquine. Preincubation with chloroquine diminished the capacity of DDC to induce TT protein specific T cell proliferation (70-80%), but was not effective to suppress TT peptide induced T cell responses. DDC were as potent as Langerhans cells and 5-10 x more potent than plastic adherent monocytes in the presentation of TT to autologous resting T cells. Furthermore, as few as 50 DDC (stimulator:responder ratio of 1:1000) were able to induce a significant TT specific T cell proliferation. Because a subpopulation of DDC expresses low levels of CD1a, a phenotypic marker of Langerhans cells, sorting of CD1a positive and negative DDC was performed. On a per cell basis, CD1a positive and negative DDC were equally potent at mediating TT specific T cell proliferation. Thus, DDC are able to internalize, process, and present soluble protein antigens such as TT and may therefore play an important role in the regulation of skin immune responses.


Subject(s)
Antigen-Presenting Cells/physiology , Dendritic Cells/immunology , Skin/immunology , Antigens, CD1/analysis , Dendritic Cells/metabolism , Humans , Skin/cytology , Solubility , T-Lymphocytes/physiology , Tetanus Toxoid/pharmacokinetics
20.
Antimicrob Agents Chemother ; 42(2): 298-305, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9527776

ABSTRACT

In a monocentric, double-blind, randomized trial, we examined the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin (P-HTIG). As part of the purification process, P-HTIG has undergone a heat treatment step (10 h at 60 degrees C) and the removal of Merthiolate. Forty-eight adults with a history of tetanus vaccination were randomized into four groups (n = 12 per group) to receive one of two different batches of this P-HTIG simultaneously with either tetanus-diphtheria (Td) vaccine (sham, postexposure prophylaxis of tetanus) or placebo. Local reactions at the injection site were followed for the first 3 days after injection, and systemic reactions were followed during the entire study period, i.e., up to 42 days posttreatment. Blood samples for tetanus antibody titer determination (enzyme-linked immunosorbent assay method) were drawn prior to treatment on day 0 and on days 1, 2, 3, 7, 14, 21, 28, 35, and 42. A normalization of tetanus antibody titers (subtraction of the day 0 value for each subject at each time period) was performed to assess the additive effect of P-HTIG on tetanus antibody titers. The pharmacokinetic parameters were determined by both a compartmental analysis (modelization) and a noncompartmental analysis. No severe adverse reactions were reported. The rate of local reactions at the P-HTIG injection site was 27%. All local reactions were mild and resolved within 2 days. In contrast, local reactions at the vaccine injection site were seen in 79% of the subjects. The rate of systemic reactions was similar in the P-HTIG plus Td vaccine group (33%) and in the P-HTIG plus placebo group (21%), and all these reactions were mild. In the P-HTIG plus placebo group, tetanus antibody titers rose to a maximum of 0.313+/-2.49 IU/ml after 4.4 days; in the P-HTIG plus Td vaccine group, a maximum concentration of 15.2+/-2.42 IU/ml was reached 19 days postinjection. In both groups, 100% of the patients had seroprotective levels of tetanus antibodies (> or = 0.01 IU/ml) 2 days following treatment. An anamnestic response to Td vaccine appeared 7 days postimmunization. In conclusion, P-HTIG has a good safety and pharmacokinetic profile. Our results confirm that immunoglobulin should be associated with vaccine in the treatment of tetanus-prone wounds.


Subject(s)
Immunoglobulins/administration & dosage , Tetanus Toxoid/administration & dosage , Tetanus/prevention & control , Adolescent , Adult , Double-Blind Method , Female , Humans , Male , Middle Aged , Tetanus Toxoid/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...